Year: 2024

Company Announcement No 18/2024 – November 12, 2024 Key highlights in Q3 2024Organic volume growth 8% in Q3. Total volume growth of 35% Organic net revenue increased by 8% to DKK 4,083m in Q3. Total revenue growth of 22% Market shares were gained or maintained in most countries Organic EBIT growth 25%. EBIT from acquisitions DKK 41m in Q3. Total EBIT growth 33% EBIT margin increased to 16.5% in Q3 (Q3 2023: 15.2%) PepsiCo’s beverage business in Belgium and Luxembourg was transferred to Royal Unibrew on October 1, 2024 Agreement signed on October 17, 2024 to acquire Pernod Ricards portfolio of local Nordic brands within spirits, liqueurs and local wine in Finland Agreement to sell shareholdings in Perla Browary Lubelskie S.A and Ferell sp. Z.o.o. resulting in a tax-free gain of DKK 207m recognized as financial income in Q3 Full year...

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc.  (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward...

ASHBURN, Va., Nov. 12, 2024 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2024 third quarter financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its third quarter 2024 financial results today, November 12, 2024, at 10:30 a.m. EST. To access the webcast, visit https://register.vevent.com/register/BIdfd71e0c66a04ad886e4545430153f2b. Related presentation materials will be made available on the Investors section of the Company’s website at https://investors.telos.com. In addition, an archived webcast will be available approximately two hours after the conclusion of the live event on the Investors section of the Company’s...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter of 2024 and provided an overview of its clinical programs and anticipated milestones. “As we direct our efforts and resources toward our ADC technologies and programs, we are committed...

LOS ALAMITOS, Calif. and LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the company behind MARKET.live, a leading livestream social shopping platform, and GO FUND YOURSELF!, a TV show and innovative new platform disrupting the crowd funding industry, today announced that on November 5, 2024, the Company filed its Form 10-Q report for the quarter ending September 30, 2024 demonstrating substantial and continuing financial improvements. In addition to the financial improvements, the report also highlights significant strategic initiatives and operational achievements. Financial HighlightsThe Company reported notable financial performance metrics for the quarter:Balance Sheet: $15.8 million in cash, short-term investments, and pre-paid expensesStockholders’...

LIMASSOL, Cyprus, Nov. 12, 2024 (GLOBE NEWSWIRE) — Toro Corp. (NASDAQ: TORO), (“Toro”, or the “Company”), an international energy transportation services company, today announced its results for the three months and the nine months ended September 30, 2024. Highlights of the Third Quarter Ended September 30, 2024:Total vessel revenues from continuing operations: $5.3 million, as compared to $6.5 million for the three months ended September 30, 2023, or a 18.5% decrease; Net income from continuing operations: $1.0 million, as compared to $0.2 million for the three months ended September 30, 2023, or a 400.0% increase; Net income: $1.0 million, as compared to $35.1 million for the three months ended September 30, 2023, or a 97.2% decrease; Loss per common share, basic from continuing operations: $(0.01) per share, as compared to...